NasdaqGS - Delayed Quote USD
Crinetics Pharmaceuticals, Inc. (CRNX)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:18 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,385.00
4,013.00
4,737.00
1,078.00
--
--
Operating Expense
279,332.00
226,621.00
172,619.00
108,780.00
74,953.00
--
Operating Income
-277,947.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
--
Net Non Operating Interest Income Expense
25,352.00
13,436.00
4,317.00
157.00
991.00
--
Other Income Expense
-5,945.00
-5,357.00
-353.00
-96.00
150.00
--
Pretax Income
-258,540.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
--
Net Income Common Stockholders
-258,540.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
--
Diluted NI Available to Com Stockholders
-258,540.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
--
Basic EPS
-3.76
-3.69
-3.15
-2.80
-2.42
--
Diluted EPS
-3.76
-3.69
-3.15
-2.80
-2.42
--
Basic Average Shares
68,870.00
58,071.00
51,982.00
38,436.00
30,448.00
--
Diluted Average Shares
68,870.00
58,071.00
51,982.00
38,436.00
30,448.00
--
Total Operating Income as Reported
-277,947.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
--
Total Expenses
279,332.00
226,621.00
172,619.00
108,780.00
74,953.00
--
Net Income from Continuing & Discontinued Operation
-258,540.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
--
Normalized Income
-258,540.00
-214,529.00
-164,518.00
-107,641.00
-73,812.00
--
Interest Income
25,352.00
13,436.00
4,317.00
157.00
991.00
--
Net Interest Income
25,352.00
13,436.00
4,317.00
157.00
991.00
--
EBIT
-277,947.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
--
EBITDA
-276,185.00
-221,510.00
-166,899.00
-106,780.00
-74,005.00
--
Reconciled Depreciation
1,762.00
1,098.00
983.00
922.00
948.00
--
Net Income from Continuing Operation Net Minority Interest
-258,540.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
--
Total Unusual Items Excluding Goodwill
--
--
600.00
--
--
--
Total Unusual Items
--
--
600.00
--
--
--
Normalized EBITDA
-276,185.00
-221,510.00
-167,499.00
-106,780.00
-74,005.00
--
12/31/2019 - 7/18/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EWTX Edgewise Therapeutics, Inc.
35.57
+0.17%
ACLX Arcellx, Inc.
96.86
+1.67%
JANX Janux Therapeutics, Inc.
50.03
+0.44%
NMRA Neumora Therapeutics, Inc.
16.49
-2.77%
CYTK Cytokinetics, Incorporated
54.97
+0.81%
KYMR Kymera Therapeutics, Inc.
46.41
+0.35%
RVMD Revolution Medicines, Inc.
50.43
+0.86%
PRAX Praxis Precision Medicines, Inc.
73.20
-2.30%
STOK Stoke Therapeutics, Inc.
13.00
-2.03%
BHVN Biohaven Ltd.
52.96
+2.56%